Monday 01 December 2025
Internal Reference Number: FOI_8784
Date Request Received: 21/07/2025 00:00:00
Date Request Replied To: 04/09/2025 00:00:00
This response was sent via: By Email
Request Summary: Haem Questionnaire
Request Category: Companies
| Question Number 1: I am writing to request the following information under the FOIA. Haem Questionnaires Haemophilia A In the past 12 months [latest 12 months available], how many patients have been diagnosed with the each of the following conditions in your Trust: Haemophilia A Acquired Haemophilia A (AHA) Congenital Haemophilia A with inhibitors (CHAwI) | |
| Answer To Question 1: 13 patients diagnosed with any type of Haemophilia A in the past 12 months. Due to there only being one single diagnosis code for this condition we are unable to tell the number of patients diagnosed with each specific type of Haemophilia A. | |
| Question Number 2: In the last twelve months[latest 12 months available], how many pts with Haemophilia A, have been treated with each of the following products in your Trust: Factor Eight Inhibitor Bypass Activity (FEIBA) Hemlibra (standalone) Hemlibra in combination with NovoSeven RT Hemlibra in combination with Cevenfacta NovoSeven RT Obizur Cevenfacta | |
| Answer To Question 2: 0 | |
| Question Number 3: In the last twelve months[latest 12 months available], how many patients with Acquired Haemophilia A, have been treated with each of the following products in your Trust: Factor Eight Inhibitor Bypass Activity (FEIBA) NovoSeven RT Obizur Cevenfacta | |
| Answer To Question 3: 0 | |
| Question Number 4: In the last twelve months[latest 12 months available], how many pts with Congenital Haemophilia A with Inhibitors have been treated with each of the following products in your Trust? Factor Eight Inhibitor Bypass Activity (FEIBA) Hemlibra (standalone) Hemlibra in combination with NovoSeven RT Hemlibra in combination with Cevenfacta Hemlibra in combination with FEIBA Helimbra in combination with Factor VIII NovoSeven RT Obizur Cevenfacta | |
| Answer To Question 4: 0 | |
| Question Number 5: Prothrombin Complex Concentrate (PCC) What is the total Prothrombin Complex Concentrate usage in International Units (IUs) for your Trust over the last 12 months [latest 12 months available] for each of the products below in your Trust? Prothromplex Beriplex Octaplex | |
| Answer To Question 5: The Trust uses use Octaplex – 34 boxes of 500IU and 70 boxes of 1000IU in the last 12 months. That is a total of 87,000IU | |
| Question Number 6: Can you share the Prothrombin Complex Concentrate usage in International Units for your Trust in the last 12 months [latest 12 months available] within each of the following departments, and which PCC is used? Prothromplex Beriplex Octaplex Departments Cardio-speciality General Medicine General surgery Haematology Emergency care Any other | |
| Answer To Question 6: Breakdown of Octaplex General Medicine – 20,000IU of 1000IU boxes and 5000IU of 500Iu boxes. General Surgery – 38,000 (1000IU) and 6000 (500IU) Emergency care – 25,000 (1000IU) and 8000 (500IU | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
